Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review
Sign Up to like & getrecommendations! Published in 2021 at "Advances in Therapy"
DOI: 10.1007/s12325-021-01989-z
Abstract: Despite the availability of established treatments, heart failure (HF) is associated with a poor prognosis and its management is suboptimal, highlighting the need for new options for treatment and prevention. Patients with type 2 diabetes… read more here.
Keywords: type diabetes; sglt 2is; heart; treatment ... See more keywords
Comparison of glucagons like peptide-1 receptor agonists and dipeptidyl peptide-4 inhibitors regarding cardiovascular safety and mortality in type 2 diabetes mellitus: A network meta-analysis.
Sign Up to like & getrecommendations! Published in 2020 at "Primary care diabetes"
DOI: 10.1016/j.pcd.2020.08.012
Abstract: AIM The effects of dipeptidyl peptide-4 inhibitors (DPP-4is) and sodium-glucose cotransporter-2 inhibitors (SGLT-2is) on type 2 diabetes mellitus (T2DM) on cardiovascular events and all-cause mortality were compared. METHODS The literature on DPP-4is and SGLT-2is treatment… read more here.
Keywords: peptide; dpp 4is; mortality; sglt 2is ... See more keywords
Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists
Sign Up to like & getrecommendations! Published in 2017 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2017.1318061
Abstract: ABSTRACT Introduction: Both sodium-glucose co-transporter-2 inhibitors (SGLT-2Is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been consistently found to lower blood glucose, body weight and systolic blood pressure (SBP) in patients with type 2 diabetes mellitus… read more here.
Keywords: glp 1ras; sglt 2is; canagliflozin 300; receptor agonists ... See more keywords
Amelioration of endothelial dysfunction by sodium glucose co‐transporter 2 inhibitors: pieces of the puzzle explaining their cardiovascular protection
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Pharmacology"
DOI: 10.1111/bph.15850
Abstract: Sodium glucose co‐transporter 2 inhibitors (SGLT‐2is) improve cardiovascular outcomes in both diabetic and non‐diabetic patients. Preclinical studies suggest that SGLT‐2is directly affect endothelial function in a glucose‐independent manner. The effects of SGLT‐2is include decreased oxidative… read more here.
Keywords: sglt 2is; glucose transporter; sodium; transporter inhibitors ... See more keywords
Do GLP‐1RAs and SGLT‐2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.1111/dom.13805
Abstract: While recent cardiovascular safety trials (CVST) concerning newer diabetes medications included mostly white participants, results are being generalized to all races in recent guidelines. This raises a controversial question regarding the appropriateness of applying CVST… read more here.
Keywords: black patients; patients type; glp 1ras; 1ras sglt ... See more keywords
Sodium‐glucose co‐transporter‐2 inhibitors and protection from cardiovascular death: Is it all about heart failure?
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes"
DOI: 10.1111/dom.14444
Abstract: To the Editor: The results of the EMPA-REG Outcome trial heralded the cardiovascular (CV) relevance of sodium-glucose co-transporter-2 inhibitors (SGLT-2is), showing an unprecedented reduction of CV death by 38% over standard of care. Then, results… read more here.
Keywords: death; analysis; sglt 2is; empa reg ... See more keywords
Secular trends in the utility of SGLT-2 inhibitors in heart failure patients with type 2 diabetes mellitus across Metro South Health hospitals in South-East Queensland.
Sign Up to like & getrecommendations! Published in 2022 at "Internal medicine journal"
DOI: 10.1111/imj.15993
Abstract: BACKGROUND The 2018 Australian Heart Failure (HF) guidelines strongly recommended commencing sodium-glucose co-transporter-2 inhibitors (SGLT-2is) in HF patients with type 2 diabetes mellitus (T2DM). The uptake of SGLT-2is for HF patients with T2DM in our… read more here.
Keywords: patients type; sglt 2is; heart failure; health ... See more keywords
Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "BMJ Open"
DOI: 10.1136/bmjopen-2022-061807
Abstract: Objective To compare the efficacy and safety between and within glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT-2is) in overweight or obese adults with or without diabetes mellitus. Methods PubMed, ISI Web… read more here.
Keywords: sglt 2is; safety; overweight obese; efficacy ... See more keywords
The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy"
DOI: 10.2147/dmso.s375559
Abstract: Abstract Diabetes and obesity are growing problems worldwide and are associated with a range of acute and chronic complications, including acute myocardial infarction (AMI) and stroke. Novel anti-diabetic medications designed to treat T2DM, such as… read more here.
Keywords: blood brain; sglt 2is; brain barrier; glp 1ras ... See more keywords
The Extraglycemic Effect of SGLT-2is on Mineral and Bone Metabolism and Bone Fracture
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2022.918350
Abstract: Type 2 diabetes mellitus (T2DM) is a risk factor for osteoporosis. The effects of T2DM and anti-diabetic agents on bone and mineral metabolism have been observed. Sodium–glucose co-transporter 2 inhibitors (SGLT-2is) promote urinary glucose excretion,… read more here.
Keywords: metabolism; sglt 2is; effect; bone ... See more keywords
Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors vs. Dipeptidyl Peptidase-4 Inhibitors in Frail People With Diabetes Who Were Recently Hospitalized
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.886834
Abstract: Introduction: Sodium-glucose cotransporter-2 inhibitors (SGLT-2Is) reduce heart failure (HF) hospitalizations and major adverse cardiovascular events (MACE) in general type 2 diabetes populations. The objective of this study was to determine whether SGLT-2Is vs. dipeptidyl peptidase-4… read more here.
Keywords: sglt 2is; frail people; glucose cotransporter; mortality ... See more keywords